Protocols to Trim Mastitis in your Herd | Boehringer Ingelheim US
Read more on how the Boehringer Ingelheim mastitis grading chart protocols lead to creating better informed mastitis treatment decisions in livestock.
Search
We get data science
Data scientists and engineers at Boehringer don't have to field the usual ill-conceived questions and comments. Here's their guide on what not to say!
Newsletter Thank you
Newsletter Thank you
3FLEX® 250-Dose Option & Vaccine Mixing | Boehringer Ingelheim US
Click here to find out more about Boehringer Ingelheim's 3FLEX® 250-Dose option & new vaccine mixing procedures, preventing major swine respiratory disease.
A Planned Safety Net for Patients in Need
A Planned Safety Net for Patients in Need
Your Milestones Drive Ours
Learn more about the experiences of living with nonsmall cell lung cancer and cholangiocarcinoma as well as caring for a loved one during a cancer journey.
Introducing Ingelvac Provenza™ | Boehringer Ingelheim US
Find out more on our new swine vaccine, offering increased protection against influenza strains affecting 70% of growing pigs annually.
SPEVIGO approved for expanded indications in China and the US
FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg
How to Help Prevent Lyme Disease in Your Dog | Boehringer Ingelheim US
Click here to learn more about steps that pet owners can take to help prevent Lyme Disease in dogs.
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Internal application
Internal applications | FAQ
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Why today’s depression trials demand smart new approaches
Why today’s depression trials demand smart new approaches
Online application
Online application | FAQ
Work life wellness
We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
Submit Your Partnering Opportunity
Submit Your Partnering Opportunity
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
Arising Vaccines to Help Zoo Elephants | Boehringer Ingelheim US
Find out how Boehringer Ingelheim is developing vaccines to help North African zoo elephants suffering from deadly infections and illness.
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
Full data announced in DINAMO trial in young people with T2D
Jardiance (empagliflozin) tablets is the first SGLT2 inhibitor to show statistically significant
Interview with Michael Schmelmer
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC